Sugi Predict

Sugi Predict / Compounds / SCHEMBL4826137

SCHEMBL4826137

SCHEMBL4826137

Nc1ncnc2c1c(I)nn2C1CCN(C(=O)O)C1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 9/20 0.67
▸ JAK3 P52333 8/20 0.67
▸ EGFR P00533 5/20 0.67
▸ CDC7 O00311 1/20 0.61
▸ PLK4 O00444 1/20 0.61
▸ DYRK3 O43781 1/20 0.61
▸ PRKD3 O94806 1/20 0.61
▸ MAP4K4 O95819 1/20 0.61
▸ NTRK1 P04629 1/20 0.61
▸ INSR P06213 1/20 0.61
▸ LCK P06239 1/20 0.61
▸ FYN P06241 1/20 0.61
▸ CDK1 P06493 1/20 0.61
▸ RET P07949 1/20 0.61
▸ ROS1 P08922 1/20 0.61
▸ SRC P12931 1/20 0.61
▸ FER P16591 1/20 0.61
▸ PRKACA P17612 1/20 0.61
▸ RPS6KB1 P23443 1/20 0.61
▸ CDK2 P24941 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28399962 1.00 JAK2 (0.67) JAK2JAK3EGFRCDC7PLK4
SCHEMBL25334338 1.00 JAK2 (0.67) JAK2JAK3EGFRCDC7PLK4
SCHEMBL4827998 0.93 EGFR (0.77) JAK2JAK3EGFRCDC7PLK4
SCHEMBL13860290 0.93 EGFR (0.77) JAK2JAK3EGFRCDC7PLK4
SCHEMBL27586636 0.93 EGFR (0.77) JAK2JAK3EGFRCDC7PLK4
SCHEMBL5802174 0.93 JAK2 (0.67) JAK2JAK3EGFRCDC7PLK4
SCHEMBL3782927 0.90 EGFR (0.63) JAK2JAK3EGFRCDC7PLK4
SCHEMBL17235861 0.87 EGFR (0.88) JAK2JAK3EGFRKDRJAK1
SCHEMBL30082483 0.87 EGFR (0.88) JAK2JAK3EGFRKDRJAK1
SCHEMBL17267791 0.87 EGFR (0.88) JAK2JAK3EGFRKDRJAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115485281-B FGFR and mutation inhibitor thereof, and preparation method and application thereof 上海和誉生物医药科技有限公司 2023-11-21 — — CN disclosed
CN-116514806-A Biological inhibitor containing acrylketone, preparation method and application thereof 上海翰森生物医药科技有限公司 2023-08-01 — — CN disclosed
US-11696917-B2 Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound TAIHO PHARMACEUTICAL CO., LTD. (JP) 2023-07-11 — — US disclosed
CN-115485281-A FGFR and mutation inhibitor thereof, and preparation method and application thereof 上海和誉生物医药科技有限公司 2022-12-16 — — CN disclosed
CN-114790209-A Optimized combinations and their use for the treatment of cancer and autoimmune diseases 浙江导明医药科技有限公司 2022-07-26 — — CN disclosed
CN-113260618-A Dimethoxybenzene compound analogue, method for analyzing compound and standard substance of compound 大鹏药品工业株式会社 2021-08-13 — — CN disclosed
CN-111349099-A Optimized drug combinations and their use for the treatment of cancer and autoimmune diseases 浙江导明医药科技有限公司 2020-06-30 — — CN disclosed
CN-108295073-B Polyfluoro compounds as bruton's tyrosine kinase inhibitors 浙江导明医药科技有限公司 2020-06-16 — — CN disclosed
CN-107406454-B Optimized drug combinations and their use for the treatment of cancer and autoimmune diseases 浙江导明医药科技有限公司 2020-05-19 — — CN disclosed
EP-3345907-B1 PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS OR SALTS THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2020-04-22 — — EP disclosed
US-9533991-B2 Inhibitors of Bruton's tyrosine kinase PHARMACYCLICS LLC (US) 2017-01-03 — — US disclosed
US-20160031891-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC 2016-02-04 — — US disclosed
US-7332497-B2 As inhibitors of protein kinases ABBOTT GMBH & CO KG (DE) 2008-02-19 — — US disclosed
EP-1385524-A4 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO KG (DE) 2006-02-01 — — EP disclosed
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 — — US disclosed
CN-1520298-A Pyrazolopyrimidines as therapeutic agents �����ʩ���عɷݹ�˾ 2004-08-11 — — CN disclosed
EP-1385524-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS Abbott GmbH & Co. KG (DE) 2004-02-04 — — EP disclosed
US-20040006083-A1 Pyrazolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2004-01-08 — — US disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 — — US disclosed
WO-2002080926-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO. KG (DE) 2002-10-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006083-A1 Pyrazolopyrimidines as therapeutic agents DPYD, UGT1A1, ABCB1 JAK2 1515/4885JAK3 1336/4885EGFR 1992/4885
US-11696917-B2 Agent enhancing antitumor effect using pyrazolo[3,4-d]pyrimidine compound ZYX, DPYD, ZFX JAK2 93/4885JAK3 196/4885EGFR 2082/4885
US-20160031891-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE BTK, LYN, SYK JAK2 22/4885JAK3 73/4885EGFR 739/4885
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 JAK2 1212/4885JAK3 1066/4885EGFR 2229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.